The role of FDG-PET and bone marrow examination in lymphoma staging

Annals of Oncology

Volumn 23, Issue SUPPL. 10, 2012, Pages

  El Najjar, I ^a   Barwick, T ^b   Avril, N ^a   Montoto, S ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

Bone marrow biopsy; FDG PET; Lymphoma; Prognosis; Stage

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; BONE MARROW BIOPSY; BONE MARROW EXAMINATION; BONE MARROW METASTASIS; CANCER INFILTRATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; FALSE NEGATIVE RESULT; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; LYMPH NODE METASTASIS; LYMPHOMA; MANTLE CELL LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 84866758055     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds316     Document Type: Article

References (16)

1. Carbone PP, Kaplan HS, Musshoff K et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860-1861.
2. Juweid ME, Stroobants S, Hoekstra OS et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571-578.
3. Trotman J, Fournier M, Lamy T et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol 2011; 29: 3194-3200.
4. 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 2001; 86: 266-273.
5. Hutchings M, Loft A, Hansen M et al. Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica 2006; 91: 482-489.
6. Moog F, Bangerter M, Diederichs CG et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998; 206: 475-481.
7. Partridge S, Timothy A, O'Doherty MJ et al. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol 2000; 11: 1273-1279.
8. Blum RH, Seymour JF, Wirth A et al. Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma 2003; 4: 43-49.
9. Scott AM, Gunawardana DH, Wong J et al. Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging 2009; 36: 347-353.
10. 18F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging 2010; 37: 2307-2314.
11. Naumann R, Beuthien-Baumann B, Reiss A et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer 2004; 90: 620-625.
12. Young CS, Young BL, Smith SM. Staging Hodgkin's disease with 18-FDG PET. Comparison with CT and surgery. Clin Positron Imaging 1998; 1: 161-164.
13. Wirth A, Foo M, Seymour JF et al. Impact of [18F] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2008; 71: 213-219.
14. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 2005; 46: 958-963.
15. 18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 2001; 12: 825-830.
16. Elstrom R, Guan L, Baker G et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003; 101: 3875-3876.